Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials

Maureen G Maguire; Ebenezer Daniel; Ankoor R Shah; Juan E Grunwald; Stephanie A Hagstrom; Robert L Avery; Jiayan Huang; Revell W Martin; Daniel B Roth; Alessandro A Castellarin; Sophie J Bakri; Stuart L Fine; Daniel F Martin; Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group)

doi:10.1016/j.ophtha.2013.03.017

Back

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials

Journal article

Open access

Peer reviewed

Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials

Maureen G Maguire, Ebenezer Daniel, Ankoor R Shah, Juan E Grunwald, Stephanie A Hagstrom, Robert L Avery, Jiayan Huang, Revell W Martin, Daniel B Roth, Alessandro A Castellarin, …

Ophthalmology (Rochester, Minn.), Vol.120(10), pp.2035-2041

10/2013

DOI: 10.1016/j.ophtha.2013.03.017

PMCID: PMC3758381

PMID: 23706946

Files and links (1)

url

http://doi.org/10.1016/j.ophtha.2013.03.017View

Open Access

Abstract

To assess the influence of drug; dosing regimen; and traditional, nontraditional, and genetic risk factors on the incidence of choroidal neovascularization (CNV) in the fellow eye of patients treated for CNV with ranibizumab or bevacizumab. Cohort study of patients enrolled in a multicenter, randomized clinical trial. Patients with no CNV in the fellow eye at the time of enrollment in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). Eligibility criteria for the clinical trial required that study eyes have evidence on fluorescein angiography and optical coherence tomography of CNV secondary to age-related macular degeneration (AMD) and visual acuity between 20/25 and 20/320. Treatment for the study eye was assigned randomly to either ranibizumab or bevacizumab and to 3 different regimens for dosing over a 2-year period. The genotypes for 4 single nucleotide polymorphisms (SNPs) associated with risk of AMD were determined. Only patients without CNV in the fellow eye at baseline were considered at risk. The CATT ophthalmologists examined patients every 4 weeks through 2 years and recorded treatment for CNV in the fellow eye. Development of CNV in the fellow eye. Among 1185 CATT participants, 727 (61%) had no CNV in the fellow eye at enrollment. At 2 years, CNV had developed in 75 (20.6%) of 365 patients treated with ranibizumab and in 60 (16.6%) of 362 patients treated with bevacizumab (absolute difference, 4.0%; 95% confidence interval [CI], -1.7% to 9.6%; P = 0.17). The risk ratio for pro re nata dosing relative to monthly dosing was 1.1 (95% CI, 0.8-1.6). Greater elevation of the retinal pigment epithelium and fluid in the foveal center of the study eye were associated with increased incidence of CNV in the fellow eye. Incidence was not associated with genotype on rs1061170 (CFH), rs10490924 (ARMS2), rs11200638 (HTRA1), and rs2230199 (C3; P>0.35). Through 2 years, there was no statistically significant difference between ranibizumab and bevacizumab in incidence of CNV in the fellow eye. Genotype on 4 SNPs previously found to be associated with AMD did not affect the risk of CNV in the fellow eye among CATT patients. Proprietary or commercial disclosure may be found after the references.

Choroidal Neovascularization - epidemiology

Intravitreal Injections

Humans

Middle Aged

Male

Macular Degeneration - drug therapy

Bevacizumab

Incidence

Dose-Response Relationship, Drug

Choroidal Neovascularization - drug therapy

Choroidal Neovascularization - pathology

Ranibizumab

Serine Endopeptidases - genetics

Aged, 80 and over

Angiogenesis Inhibitors - therapeutic use

Female

Complement C3 - genetics

Genetic Predisposition to Disease

Antibodies, Monoclonal, Humanized - therapeutic use

Macular Degeneration - complications

High-Temperature Requirement A Serine Peptidase 1

Genotype

Proteins - genetics

Macular Degeneration - genetics

Aged

Polymorphism, Single Nucleotide

Complement Factor H - genetics

Choroidal Neovascularization - genetics

Cohort Studies

Details

Title: Subtitle: Incidence of choroidal neovascularization in the fellow eye in the comparison of age-related macular degeneration treatments trials
Creators: Maureen G Maguire - Department of Ophthalmology, University of Pennsylvania, Philadelphia, Pennsylvania
Ebenezer Daniel
Ankoor R Shah
Juan E Grunwald
Stephanie A Hagstrom
Robert L Avery
Jiayan Huang
Revell W Martin
Daniel B Roth
Alessandro A Castellarin
Sophie J Bakri
Stuart L Fine
Daniel F Martin
Comparison of Age-Related Macular Degeneration Treatments Trials (CATT Research Group)
Contributors: James C Folk (Contributor) - University of Iowa, Ophthalmology and Visual Sciences
Douglas B Critser (Contributor) - University of Iowa, The University of Iowa Institute for Vision Research
Stephen R Russell (Contributor) - University of Iowa, Ophthalmology and Visual Sciences
Heather A Stockman (Contributor) - University of Iowa, Ophthalmology and Visual Sciences
Resource Type: Journal article
Publication Details: Ophthalmology (Rochester, Minn.), Vol.120(10), pp.2035-2041
DOI: 10.1016/j.ophtha.2013.03.017
PMID: 23706946
PMCID: PMC3758381
NLM abbreviation: Ophthalmology
ISSN: 0161-6420
eISSN: 1549-4713
Publisher: United States
Grant note: U10 EY017828 / NEI NIH HHS U10 EY017826 / NEI NIH HHS U10 EY017825 / NEI NIH HHS U10 EY017823 / NEI NIH HHS
Language: English
Date published: 10/2013
Academic Unit: The University of Iowa Institute for Vision Research; Ophthalmology and Visual Sciences
Record Identifier: 9983980068302771

Metrics

51 Record Views

67 Times Cited - Web of Science